Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.

This study highlighted the importance of stromal types and stromal PD-L1 status in determining clinical outcomes in patients with breast cancer, and suggested that stromal type classification might be readily incorporated into routine clinical risk assessment following curative resection or optimal therapeutic design.